Under the 10-year lease agreement, Biogen has the option to purchase Eisai’s oral solid dose facility. Approximately 50 Eisai personnel are expected to become Biogen employees in early 2013. Eisai currently has approximately 225 full-time employees at its RTP site.
“We view our supply chain as a lifeline to patients, designed to deliver quality therapies wherever and whenever they are needed,” said John G. Cox, executive vice president of Pharmaceutical Operations and Technology, for Biogen Idec. “This innovative capacity-sharing relationship with Eisai fits strategically in our global drug supply network, particularly as we advance our oral therapeutics.”
"We look forward to collaborating with Biogen Idec to continue the proud history of drug manufacturing excellence here at our RTP site," said Lou Arp, general manager of the Eisai RTP site and president of Global Oncology Manufacturing, for Eisai Inc. "Our alliance will enable both companies to focus on respective areas of expertise while continuing to deliver high-quality and innovative products to patients. Moreover, employees will benefit by working in a highly collaborative environment that offers opportunities to further cultivate their careers.”